Background: High-dose chemotherapy (HDT) with autografting of hematopoietic stem cells induces up to 50% of complete remissions in patients with multiple myeloma. Cases of molecular remissions have been reported. However, qualitative assays determine only the absence or presence of a monoclonal population depending on their sensitivity. Therefore reliable and sensitive methods to quantitate tumor loads are neccessary.
Introduction
Multiple myeloma (MM) is a B-cell malignancy characterized by a monoclonal expansion of plasma cells, paraproteinemia and lytic bone lesions. High-dose chemotherapy (HDT) with autologous bone marrow or peripheral blood stem cell (PBSC) transplantation results in five times higher complete remission (CR) rates and prolonged overall survival (OS) compared to conventional treatment [1] . Nonetheless, most patients eventually relapse, indicating the survival of malignant cells with proliferative capacity even after these dose-intensified regimens. Efforts are therefore directed towards eradicating all cells of the malignant clone by sequential HDT and elimination of tumor cells in the autografts. To assess the efficacy of sequential HDT a quantitative method capable of detecting tumor loads as low as 0.001% in peripheral blood (PB) and bone marrow (BM) is neccessary [2, 3] .
We have established a quantitative PCR assay with allele-specific primers (ASOs) complementary to the hypervariable CDR3 region of the immunoglobulin heavy chain gene that is based on the method of limiting dilutions. A single hit model was used and positive and negative PCR reactions at each dilution level were analysed using the methods of likelihood maximization and X minimization as described byTaswell [4] to determine the percentage of malignant cells in a sample.
Materials and methods

Nucleic acid extraction
A BM sample taken at diagnosis or prior to mobilization therapy was used to identify the CDR3 region involved in the immunoglobulin gene rearrangement of the malignant clone. Informed consent was obtained from each patient prior to sample collection. Mononuclear cells from BM samples were obtained following separation by Ficoll (Biochrom, Berlin, Germany). Cells from the myeloma cell line U266 were pelleted and used directly for DNA extraction. Genomic DNA was isolated by cell lysis with nonionic detergents, RNase A and Proteinase K (Boehringer, Mannheim, Germany) digestion followed by phenol extraction. DNA was precipitated with isopropanol and the pelleted DNA redissolved in TE 10/1 (10 mM Tris-CI pH 8.0, lmM EDTA). DNA concentration was determined by optical density (OD) measurement.
Total RNAwas extracted according to the method of Chomczynski and Sacchi [5] omitting the phenol extraction step, using instead the RNeasy collumns (Qiagen, Hilden, Germany) for further purification. After quantitation by ultraviolet (UV) spectrophotometry, RNA was adjusted to a concentration of 0.66 ug/ul.
The integrity of the isolated nucleic acids was confirmed by ethidiumbromide stained agarose gels for DNA and by denaturating gels containing 2.2 mM formaldehyde for RNA.
cDNA synthesis and RT-PCR cDNA synthesis and RT-PCR were performed with reverse transcriptase and Taq polymerase following the manufacturers instructions (Perkin Elmer, Weiterstadt, Germany). Briefly, 2 ug of total RNA was added to a mixture containing lx PCR buffer (10 mM Tris-Cl pH 8.3, 50 mM KC1, 0.1% Triton X-100, 0.001% gelatine), 5 mM MgCl 2 , 10 mM DTT, 1 mM of each deoxy nucleoside triphosphate (dNTPs), 2.5 uM random hexamers, 20 U RNase inhibitor and 200 U MoMLV reverse transcriptase. The final volume was 20 ul. Reverse transcription was performed at 42 °C for 15 minutes.
Consensus primers to the the V H -and the J H -region of the immunoglobulin heavy chain gene on chromosome 14 [6] were extended at the 5'-ends to allow cloning into the pdirect vector (Clontech, Palo Alto CA, USA). Sequences were as follows (additional sequences in italics): 5'-CTG GTT CGG CCC A AC ACG GC(C/T) (G/QTG TAT TAC TGT 3' (FR3A-CL, V H -primer) and 5'-CTC GCT CGC CCA TGA GGA GAC GGT GAC C-3' (UH-CL, J H -primer). CDR3 consensus PCR was performed on cDNA isolated from BM samples of patients prior to HDTand on cDNA from U266 cells. A total volume of 100 ul per reaction contained 1.2 uM of each consensus primer, 2 mM MgCl 2 , 200 uM of each dNTP, 10 ul of 10 x PCR buffer and 2 U of Taq DNA polymerase (Perkin Elmer, Weiterstadt, Germany). Amplification conditions were: five minutes preheating at 94 °C, 40 cycles of one minute denaturation at 94 °C, one minute annealing at 60 °C and 1.5 minutes extension at 72 °C, followed by a final extension of 8.5 minutes at 72 °C. Each aliquot of RNA was amplified in parallel using commercially available primers for the P-actin gene (Stratagene, Heidelberg, Germany). Additionally, with each experiment a negative control without added RNA was performed.
Cloning and sequencing of CDR3 amplification products Amplified CDR3 regions were electrophoresed on ethidium bromide stained 5% Nusieve agarose gels (FMC, Rockville, ME, USA) and visualized under UV light. DNA of the expected size was excised from the gel and purified using the EasyPure DNA Purification kit (Biozym, Gottingen, Germany).
PCR products were cloned using the PCRdirect cloning system (Clontech) featuring the blue-white screening for identification of recombinant plasmids. Plasmid DNA was cycle-sequenced after lysis of bacterial clones with 10 mM Tris-Cl pH 7.5, 1 mM EDTA and 100 ug/ml of Proteinase K (Boehringer). Sequencing was done with the Sequitherm Cycle Sequencing kit (Biozym) on an automated sequencer (Alf-express, Pharmacia, Freiburg, Germany).
The CDR3 region of the malignant clone was identified by its predominant occurrence in contrast to polyclonal CDR3 regions that are rarely encountered more than once among the analysed PCR products.
Design of ASO primers
Sequences of CDR3 regions of the malignant clones were compared to known CDR3 sequences in order to discriminate between conserved and highly variable segments. For each patient and the U266 myleoma cell line ASO primers complementary to highly variable segments were devised. Oligonucleotides were purchased commercially (MWG Biotech, Ebersberg, Germany). Specificity was tested by amplifying DNA from the patient's BM sample as positive control and bufiy-coat-DNA of healthy donors as negative control.
Quantitative PCR-assay (qPCR) Integrity of sample DNA was checked by amplification of 2000 ng DNA using primers complementary to sequences of the ic/2-gene (Dianova, Hamburg, Germany). PCR was performed as described previously [7] , DNA from 330,000 cells per sample was serially diluted in 0.5 log steps and amplified using the appropriate ASO together with LJH-CL as antisense-primer. At each dilution level five identical PCR-reactions were processed simultaneously. Each PCR was performed twice, thus resulting in 10 PCR reactions per dilution level. Each qPCR-reaction of 50 ul contained up to 2000 ng genomic DNA, 5 ul GeneAmp 10 x PCR buffer II, 2 mM MgCl 2 , 0.2 mM of each dNTP, 1 uM of each primer and 2.5 U of Amplitaq-Gold-DNA-polymerase (Perkin Elmer). Amplification conditions were: seven minutes preheating at 94 °C, 62 cycles of one minute denaturation at 94 °C and one minute combined annealing and extension at 65 °C, followed by a final extension of five minutes at 65 °C. PCR-products were electrophoresed on ethidium bromide stained 5%-agarose gels and visualized under UV light. Each sample was diluted until no more PCR product was detectable. Always a negative control was amplified along with the diluted sample DNA. Precautions necessary for the avoidance of cross-contaminations were those described by Kwok and Higuchi [8] .
DNA and RNA were prepared in a laboratory set apart from the laboratory where the PCR products were analysed.
Determination of the percentage of malignant cells
The number of tumor cells in a sample was calculated based upon Poisson distribution statistics of positive and negative reactions of the qPCR at each dilution level.
As starting value for Newton's method of iterative approximation the weighted mean estimation was used. The likelihood maximization and the x 2 minimization were calculated as described by Taswell [4] . A computer program was written in C (Watcom C, Power-Soft, Waterloo, Canada) to perform the necessary calculations. This program running under DOS® on an IBM® compatible PC or the C source code can be obtained according to the terms and conditions for copying, distribution and modification of programs under the GNU general public license agreement (see contact address).
Immunofluorescence staining and flow cytometry Mononuclear cells were resuspended in 1% PBS to a concentration of 1.5-2 x 10 IO /1. For 30 min 50 ul cell suspension was incubated at 4°C with fluorescein isothiocyanate conjugated monoclonal antibodies CD38 (Immunotech, Hamburg, Germany) and anti-human K and X light chains (Dianova). Added were 100 ul OptiLyse B solution (Immunotech), followed by an incubation step of 15 minutes at room temperature. Residual erythrocytes were lysed with aqua destillata. The mixture was washed once in PBS. Immunofluorescence analysis was performed using a five-parameter FACScan (Becton Dickinson, Heidelberg, Germany) as described previously [9] , Preparation and analysis of samples with simulated tumor loads Plasmids carrying the CDR 3 regions of the malignant clones of two patients were isolated from bacterial clones and purified using the QIAwell 8 Plus system (Qiagen). Plasmid DNA concentration was determined by OD measurement. Knowing the mass of a single pdirect vector and the concentration of the plasmid DNA, the number of copies per ul was calculated. Plasmids were diluted in 10-fold steps until feasible concentrations were reached. One plasmid plus six pg of human placental DNA (Clontech) were used to simulate one diploid genome of a malignant cell. By mixing different quantities of placental DNA with pdirect vectors carrying the appropriate CDR3 region, samples containing simulated tumor loads of 100, 10, 1, 0.1, 0.01 and 0.001% were generated. qPCR was performed as described above. After decadic logarithmization, results were analysed using the Multiple Regression Module of Statistica for Windows (StatSoft, Tulsa OK, USA). 
Results
Sequences of the myeloma CDR3 regions and ASO primers
The amplification products of the malignant clones of patients A and B and the U266 cell line displayed distinct bands of approximately 110, 120 bp and 140 bp. Table 1 denotes the sequences of the CDR3 regions of the two myeloma clones and the U266 cell line. For each malignant clone, four ASO primers were designed and tested by amplifying DNA from the initial BM-sample and buffy-coat-DNA of healthy donors. At least one primer per myeloma clone generated the PCR product of the expected size while not amplifying buffycoat-DNA. Sequences of the ASO primers chosen are given in Table 1 .
Validation of the qPCR assay
Since Poisson analysis for quantitation of PCR results is based upon single-hit events, we tested the sensitivity of our PCR assay to detect a single copy of the myeloma CDR3 region in a PCR tube. DNA of 330,000 U266 cells was diluted up to 3,300,000-fold and analysed by qPCR. The U266 template was detected in seven of 10 cases at 1: 330,000 (equivalent to a mean of one cell per tube), in three of 10 cases at 1:1,000,000 (mean of 1/3 cell per tube) and in one of 10 cases at 1: 3,330,000 (mean of 1/10 cell per tube). The result of the x 2 -minimization was 115%.
To prove the accuracy of the qPCR assay with patient specimens, a BM sample from patient A was analysed by FACS for CD 38++ and K/X restricted plasma cells and Table 2 . qPCR results of samples with simulated tumor loads using ASO primers of patients A and B.
100 bp Figure 1 . Analysis of the tumor load of a BM-sample from patient A. DNA from 330,000 cells was assessed-Five of five PCR reactions were positive at a dilution level of 1: 3,300, three of five at 1:10,000 and none of five at 1:33,000. The result of the x 2 -approximation was a percentage of malignant cells of 2.5%. The specific PCR product is 78 bp in length. by qPCR. The results were 1.4 and 2.5% respectively (Figure 1 ). To further test the qPCR assay with different ASO primers and varying percentages of malignant cells, plasmids carrying the CDR3 regions of two patients were diluted into placental DNA to simulate percentages of malignant cells ranging from 10% down to 0.001%. The results of the qPCR diverged by no more than a factor of 1.6 from the expected values even at the lowest amounts of tumor cells. Linear regression analysis after decadic logarithmization yielded a correlation coefficient of 0.9969 (P = 0.000014) and 0.997 (P = 0.000013) respectively (Table 2, Figure 2 ).
Discussion
We have established a quantitative PCR assay for the detection of malignant cells with ASO primers in specimens from patients with MM. By performing three different validation experiments, we were able to demonstrate that the qPCR features high sensitivity, a sufficient accuracy and reliability.
A prerequisite for the statistical procedures of likelihood maximization and % 2 minimization is that a single copy of the CDR3 region of the malignant clone can be detected in a PCR tube ('single-hit-model'). By diluting DNA from U266 cells we were able to demonstrate that this requirement was met. Furthermore, the tumor load of 115% calculated by the x 2 minimization fit very well with the actual value of 100%, especially when taking into account that the PCR amplification is an exponential process. Assessment of a BM sample demonstrated that the qPCR is feasible with patient specimens. Analysis of samples with simulated tumor loads of down to 0.001% showed that the qPCR is a reliable tool for quantitating malignant cells especially in samples with very low amounts of malignant cells. Schiller et al. and Vescio et al. [2, 3] found indeed tumor loads of leukapheresis products, BM and PB in MM in the range of 1 to 0.001%, using a similar assay.
To quantitate PCR results, essentially four different methods have been described. While the measurement of the amount of PCR product, the coamplification of a control gene and the competitive PCR rely on the quantitation of the generated product, the limiting dilution assay evaluates only positive and negative PCR reactions at different dilution levels. Since amplification efficiencies and hence the amounts of PCR product can vary substantially from tube to tube in spite of identical and simultaneous processing of reaction mixtures [10] , limiting dilutions are less prone to errors caused by these deviations [11, 12] . Furthermore, in MM no ubiquitous PCR marker exists, which prevents the application of a competitor or coamplification system for all ASO primers. Thus, limiting dilutions seem to be the most feasible approach to quantitative PCR in MM.
Here, sequential HDT is increasingly considered for the treatment of patients with MM younger than 65 years. Results of Corradini et al. and Billadeau et al. [13, 14] indicate that almost all patients remain PCRpositive after single HDT. Bjorkstrand et al. [15] reported that a double HDT followed by autologous BM or PBSC transplantation can achieve molecular remissions (MR) in BM samples of patients with MM. However, the assessment of minimal residual disease (MRD) by qualitative methods depends on their sensitivitity. The detection level of the immunoglobulin gene fingerprinting technique used by Bjorkstrand et al. is below that of PCR assays using ASO primers [13, 14] . Differences in the sensitivity might account for diverging results, indicating that the term MRD and thus, the MR status is not consistently defined. Therefore we consider the qPCR to be a useful tool in assessing MR status after sequential HDT and in evaluating the tumor load of autografts.
